HomeAI · summaries
Storia in 2 fonti
Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromab
Scribe markets its Nasdaq IPO at a $14 midpoint for ~$96M net proceeds; Scholar Rock's apitegromab awaits an FDA call on Novo Nordisk's Indiana site.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromab
Scribe markets its Nasdaq IPO at a $14 midpoint for ~$96M net proceeds; Scholar Rock's apitegromab awaits an FDA call on Novo Nordisk's Indiana site.
- ·
biopharmadive.com
Scribe secures $129M in a rare gene editing IPO
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotech companies that have gone public in 2026.